Cargando…

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer

BACKGROUND: Recurrent platinum-resistant clear-cell ovarian cancer has a low overall survival duration of 7-8 months, making it a fatal disease. Currently, chemotherapy is the major kind of treatment, but it offers little advantage. Repurposed conventional drugs have recently been found to offer the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinsuwan, Woraporn, Norchai, Phawit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266906/ https://www.ncbi.nlm.nih.gov/pubmed/37323625 http://dx.doi.org/10.1155/2023/2079654

Ejemplares similares

Screening Test on Metabolic Syndrome Using Electro Interstitial Scan Instrument
por: Norchai, Phawit, et al.
Publicado: (2020)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
por: Wu, Yawen, et al.
Publicado: (2022)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer
por: Howard, Candace M, et al.
Publicado: (2021)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
por: Morse, Christopher B., et al.
Publicado: (2017)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer
por: Burke, Morgan, et al.
Publicado: (2018)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

Successful secondary radical operation on unretractable metastatic platinum-sensitive recurrent ovarian cancer by immunotherapy: a case report
por: Sun, Li, et al.
Publicado: (2022)

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report
por: Li, Shuzhan, et al.
Publicado: (2022)

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
por: Cheng, Yuan, et al.
Publicado: (2018)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
por: Rubio Pérez, María Jesús
Publicado: (2017)

Successful nedaplatin desensitization therapy in a patient with platinum-sensitive recurrent ovarian cancer: A case report and literature review
por: Kokabu, Tetsuya, et al.
Publicado: (2022)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

Two cases of clear cell ovarian cancer in young patients
por: Ranaee, Mohammad, et al.
Publicado: (2016)

Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy
por: Fehniger, Julia, et al.
Publicado: (2018)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
por: Colombo, Nicoletta, et al.
Publicado: (2023)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
por: Roberts, D, et al.
Publicado: (2005)

Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma
por: Lewin, S, et al.
Publicado: (2012)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jcqblan82qtgu07i68nu98kslr